Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amarin Corporation plc
  6. Summary
    AMRN   US0231112063

AMARIN CORPORATION PLC

(AMRN)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
1.920 USD   -3.52%
06/16Sarissa Capital Management LP Provides Information to Shareholders of Amarin Corporation plc
CI
06/15Sarissa Capital Intends to Vote “Abstain” at the Amarin Annual Meeting
BU
06/15European ADRs Move Higher in Wednesday Trading
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/17/2022 06/21/2022 06/22/2022 06/23/2022 06/24/2022 Date
1.83(c) 1.89(c) 1.88(c) 1.99(c) 1.92(c) Last
5 402 211 3 039 483 2 273 078 2 179 660 2 676 197 Volume
+7.65% +3.28% -0.53% +5.85% -3.52% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 366 M - -
Net income 2022 -65,8 M - -
Net cash position 2022 357 M - -
P/E ratio 2022 -11,8x
Yield 2022 -
Sales 2023 344 M - -
Net income 2023 -62,2 M - -
Net cash position 2023 279 M - -
P/E ratio 2023 -12,3x
Yield 2023 -
Capitalization 762 M 762 M -
EV / Sales 2022 1,11x
EV / Sales 2023 1,41x
Nbr of Employees -
Free-Float 94,2%
More Financials
Company
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics for cardiovascular disease management. The Company operates through the development and commercialization of Vascepa segment. Its lead product, Vascepa (icosapent ethyl) capsule for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe... 
Read more
More about the company
Ratings of Amarin Corporation plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about AMARIN CORPORATION PLC
06/16Sarissa Capital Management LP Provides Information to Shareholders of Amarin Corporatio..
CI
06/15Sarissa Capital Intends to Vote “Abstain” at the Amarin Annual Meeting
BU
06/15European ADRs Move Higher in Wednesday Trading
MT
06/13European ADRs Fall Sharply Lower in Monday Trading
MT
06/13Amarin receives positive recommendation from united kingdom's (uk) national institute f..
AQ
06/10European ADRs Tumble in Friday Trading
MT
06/10Amarin's Heart Disease Drug Receives Backing for Reimbursement in UK
MT
06/10Amarin Receives Positive Recommendation from United Kingdom's (UK) National Institute f..
GL
06/10Amarin Receives Positive Recommendation from United Kingdom's (UK) National Institute f..
AQ
06/10Amarin Corporation plc Receives Positive CHMP Opinion for Icosapent Ethyl for Cardiovas..
CI
06/08European ADRs Move Lower in Wednesday Trading
MT
06/07European ADRs Move Higher in Tuesday Trading
MT
06/06AMARIN : ANNOUNCES COMPREHENSIVE COST REDUCTION PLAN TO ADDRESS MARKET DYNAMICS IN U.S. BU..
PU
06/06AMARIN CORP PLCUK : Costs Associated with Exit or Disposal Activities, Change in Directors..
AQ
06/06Amarin Corporation plc Announces Executive Changes
CI
More news
News in other languages on AMARIN CORPORATION PLC
06/16Sarissa Capital Management LP fournit des informations aux actionnaires d'Amarin Corpor..
06/15Les ADR européens sont en hausse mercredi
06/13Les ADR européens chutent fortement dans les échanges de lundi
06/10Les ADR européens chutent dans les échanges de vendredi
06/10Le médicament d'Amarin contre les maladies cardiaques reçoit l'aval pour être remboursé..
More news
Analyst Recommendations on AMARIN CORPORATION PLC
More recommendations
Chart AMARIN CORPORATION PLC
Duration : Period :
Amarin Corporation plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMARIN CORPORATION PLC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Last Close Price 1,92 $
Average target price 3,57 $
Spread / Average Target 86,0%
EPS Revisions
Managers and Directors
Karim Mikhail President, Chief Executive Officer & Director
Thomas Reilly Chief Financial Officer
Per Wold-Olsen Chairman
Steven B. Ketchum Chief Scientific Officer & Executive VP
Derek Kalinowski SVP-Manufacturing Operations
Sector and Competitors
1st jan.Capi. (M$)
AMARIN CORPORATION PLC-43.03%762
GILEAD SCIENCES, INC.-13.12%79 122
VERTEX PHARMACEUTICALS33.22%74 821
REGENERON PHARMACEUTICALS, INC.-3.01%65 993
WUXI APPTEC CO., LTD.-13.42%44 742
BIONTECH SE-48.01%32 574